TABLE 7.
Outcomes of representative clinical trials of eribulin and other drugs in nonspecific STSs.
| Drugs and dosages | Years of report | Study types | Setting | Number of patients | Outcomes | References | ||
|---|---|---|---|---|---|---|---|---|
| ORR (%) | M-PFS (months) | M-OS (months) | ||||||
| Eribulin 1.4 mg/m2/d1,8/3w | 2022 | Phase IV trial | Any-line | 252 | 8.1 | 2.5 | 10.8 | Kawai et al. (2022) |
| Eribulin 1.4 mg/m2/d1,8/3w | 2017 | Phase II trial | ≥2 line | 51 | 0 | 4.1 | 13.2 | Kawai et al. (2017) |
| Eribulin 1.4 mg/m2/d1,8/3w | 2011 | Phase II trial | ≥2 line | 115 | 4.3 | 2.1/2.9 a | - | Schoffski et al. (2011) |
| Pemetrexed 500 mg/m2/d1/3w plus cisplatin 75 mg/m2/d1/3w | 2021 | Phase II trial | ≥2 line | 37 | 13.5 | 2.6 | 52 | Kim et al. (2021) |
| Pemetrexed 500 mg/m2/d1/3w | 2013 | Phase II trial | ≥2 line | 48 | 5 | 1.6 | 6 | Hartmann et al. (2013) |
| Ifosfamide 2 g/m2/d1–2/3w plus etoposide 100 mg/m2/d1–5/3w plus cisplatin 20 mg/m2/d1–5/3w | 2000 | Phase II trial | First-line | 104 | 46 | 4.6 | 8 | Pápai et al. (2000) |
| Ifosfamide 1.5 g/m2/d1–3/3w plus etoposide 600 mg/m2/d1/3w | 1997 | Phase II trial | First-line | 86 | 41 | - | 19 | Saeter et al. (1997) |
| Cisplatin 100 mg/m2/d1/3w plus vinblastine 1.2 mg/m2/d1/3w | 1997 | Phase II trial | ≥2 line | 20 | 0 | - | - | Keohan et al. (1997) |
| Etoposide 50 mg/m2/d1–21/4w | 1997 | Phase II trial | ≥2 line | 27 | 0 | - | - | Keizer et al. (1997) |
| Epirubicin 60 mg/m2/d1–3/3w plus cisplatin 30 mg/m2/d2–5/3w | 1997 | Phase II trial | First-line | 56 | 54 | - | - | Jelić et al. (1997) |
| Etoposide 200 mg/m2/72 h–infusion/3w | 1997 | Phase II trial | ≥2 line | 16 | 0 | 1.4 | 3.7 | Crawley et al. (1997) |
| Cyclophosphamide 500 mg/m2/d1/3w plus vincristine 1.5 mg/m2/d1/3w plus doxorubicin 50 mg/m2/d1/3w plus dacarbazine 750 mg/m2/d1/3w | 1995 | Phase II trial | First-line | 142 | 28.4 | 11.2 | 11.9 | Santoro et al. (1995) |
| Cisplatin 400 mg/m2/d1–5/4w | 1990 | Phase II trial | Any-line | 40 | 15 | - | - | Budd et al. (1990) |
| Epirubicin 60 mg/m2/d1–3/3w plus cisplatin 30 mg/m2/d2–5/3w | 1990 | Phase II trial | First-line | 35 | 57 | - | - | Jelić et al. (1990) |
| Doxorubicin 70 mg/m2/d1/3w plus vindesine 3 mg/m2/d1/3w | 1990 | Phase III trial | First-line | 147 | 18 | 4 | 9.9 | Borden et al. (1990) |
| Cisplatin 120 mg/m2/3w | 1987 | Phase II trial | ≥2 line | 26 | 4 | - | - | Sordillo et al. (1987) |
| Cisplatin 120 mg/m2/3w | 1982 | Phase II trial | ≥2 line | 36 | 6 | - | - | Brenner et al. (1982) |
| Methotrexate 4 g/m2/3w | 1980 | Phase II trial | ≥2 line | 18 | 5.6 | - | - | Karakousis et al. (1980) |
STSs, soft tissue sarcomas; ORR, objective response rate; M-PFS, median progression-free survival; M-OS, median overall survival.
a
M-PFS, was 2.6, 2.9, 2.6, 2.1 months in the patients with adipocytic sarcoma, leiomyosarcoma, synovial sarcoma, and other types of STS, respectively.